Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mokelumne river	7/29/2015 1:57:34 PM
	Read Replies (1) of 2026

Eman, thanks for the discussions on ihub. I actually agree with points made by you and others. Cold chain Vitaros will not be a blockbuster but is a good way of establishing a market with proper use ahead of the room temp device. The revenue from Vitaros will help (and hopefully be sufficient to) fund debt to further RayVa and Fispemifene, assuming the costs are not too high. I reread the last press release (6/15) that concerned RayVa and the following quote caught my eye: "Apricus is seeking to accelerate our move into a more "real world setting", by advancing RayVa into later phase development. The subsequent studies will be based on at-home, on-demand treatment of spontaneous Raynaud's episodes, and will further assess safety, tolerability and efficacy of one or more doses," said Barbara Troupin, MD, Chief Medical Officer of Apricus Biosciences." (emphasis added) So up until now, I was thinking that Phase IIA and PIII would be "cold challenges" that would induce a Raynaud episode. At-home studies may take a little longer...but perhaps save on lab expenses. Maybe you could discuss this with your buddy Rich when you see him. : ) James

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next